Yuanyuan Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuanyuan Luo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Jieying Li
Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China
4 shared publicationsHao Sun
Department of Neurology, The First People's Hospital of Shuangliu District, Chengdu, West China Airport Hospital, Sichuan University, Chengdu, Sichuan 610200, China
2 shared publicationsJun Xiao
Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu China
2 shared publicationsArui Tan
Sichuan Provincial Center for Mental Health, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, China
1 shared publicationFugui Jiang
Sichuan Provincial Center for Mental Health, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, China
1 shared publicationJian Fan
Department of Neurology, West China Airport Hospital, The First People’s Hospital of Shuangliu District, Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- 8 October 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 259, 109179
Letter to the Editor: The novel VPS13D variations in autosomal recessive spinocerebellar ataxia 4
- 8 October 2025
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 259, 109179
Letter to the Editor: The novel VPS13D variations in autosomal recessive spinocerebellar ataxia 4
- Open Access
- 10 July 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-8
Steroid-responsive autoimmune psychosis with cerebrospinal fluid-restricted oligoclonal bands and positive tissue-based assay findings: a case series of three patients
Partial psychotic disorders such as autoimmune psychosis do not respond adequately to conventional antipsychotic drugs or psychotherapy. Autoimmune psychosis presents with isolated psychiatric symptoms, responds to immunotherapy, and differs from typical autoimmune encephalitis. Previous study has proposed an approach to identifying autoimmune psychosis, however, further research remains necessary to enhance our understanding of this condition. We describe 3 patients presenting with acute or recurrent psychiatric symptoms (patient 1, 2 and 3), accompanied by cognitive impairment (patient 1), autonomic dysfunction (patient 2), and/or abnormal electroencephalogram (patient 1). Brain magnetic resonance imaging results and autoimmune antibodies in cerebrospinal fluid testing were normal. However, the cerebrospinal fluid-restricted oligoclonal bands were detected in patient 1 and patient 2, while patient 3 showed positive tissue-based assay results in cerebrospinal fluid. Combined steroid therapy could enhance the limited improvement in patient 1, who had been treated with blonanserin, valproate and modified electroconvulsive therapy, and could also prevent symptom recurrence in patient 2, who received antipsychotic treatment. In contrast, in the absence of combined steroid therapy, patient 3 had only partial improvement with risperidone and valproate. Cerebrospinal fluid-restricted oligoclonal bands and tissue-based assay in cerebrospinal fluid could both provide sufficient evidence for autoimmune psychosis in the absence of clear neurological symptoms. For patients with mild psychiatric symptoms, low-dose of steroids may also be a treatment option. Autoimmune psychosis should be considered when antipsychotic drugs or modified electroconvulsive therapy are not effective in patients with psychotic disorders.
- 10 July 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-8
Open AccessSteroid-responsive autoimmune psychosis with cerebrospinal fluid-restricted oligoclonal bands and positive tissue-based assay findings: a case series of three patients
Partial psychotic disorders such as autoimmune psychosis do not respond adequately to conventional antipsychotic drugs or psychotherapy. Autoimmune psychosis presents with isolated psychiatric symptoms, responds to immunotherapy, and differs from typical autoimmune encephalitis. Previous study has proposed an approach to identifying autoimmune psychosis, however, further research remains necessary to enhance our understanding of this condition. We describe 3 patients presenting with acute or recurrent psychiatric symptoms (patient 1, 2 and 3), accompanied by cognitive impairment (patient 1), autonomic dysfunction (patient 2), and/or abnormal electroencephalogram (patient 1). Brain magnetic resonance imaging results and autoimmune antibodies in cerebrospinal fluid testing were normal. However, the cerebrospinal fluid-restricted oligoclonal bands were detected in patient 1 and patient 2, while patient 3 showed positive tissue-based assay results in cerebrospinal fluid. Combined steroid therapy could enhance the limited improvement in patient 1, who had been treated with blonanserin, valproate and modified electroconvulsive therapy, and could also prevent symptom recurrence in patient 2, who received antipsychotic treatment. In contrast, in the absence of combined steroid therapy, patient 3 had only partial improvement with risperidone and valproate. Cerebrospinal fluid-restricted oligoclonal bands and tissue-based assay in cerebrospinal fluid could both provide sufficient evidence for autoimmune psychosis in the absence of clear neurological symptoms. For patients with mild psychiatric symptoms, low-dose of steroids may also be a treatment option. Autoimmune psychosis should be considered when antipsychotic drugs or modified electroconvulsive therapy are not effective in patients with psychotic disorders.
- Open Access
- 12 January 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (1) , e8310
The psychiatric symptoms in anti‐IgLON5 disease: Case report and literature review
Key Clinical Message: Immunotherapy may be ineffective in the advanced stages of anti‐IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti‐IgLON5 disease may be associated with neurodegeneration.
- 12 January 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (1) , e8310
Open AccessThe psychiatric symptoms in anti‐IgLON5 disease: Case report and literature review
Key Clinical Message: Immunotherapy may be ineffective in the advanced stages of anti‐IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti‐IgLON5 disease may be associated with neurodegeneration.
- Open Access
- 2 August 2023
- Published by Wiley
The Psychiatric Symptoms in Anti-IgLON5 Disease: Case Report and Literature Review
The Psychiatric Symptoms in Anti-IgLON5 Disease: Case Report and Literature ReviewKey Clinical MessageImmunotherapy may be ineffective in the advanced stages of anti-IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti-IgLON5 disease may be associated with neurodegeneration.Keywords: Anti-IgLON5 disease, Psychiatric symptoms, Neurodegeneration, Immunotherapy, Case report.
- 2 August 2023
- Published by Wiley
Open AccessThe Psychiatric Symptoms in Anti-IgLON5 Disease: Case Report and Literature Review
The Psychiatric Symptoms in Anti-IgLON5 Disease: Case Report and Literature ReviewKey Clinical MessageImmunotherapy may be ineffective in the advanced stages of anti-IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti-IgLON5 disease may be associated with neurodegeneration.Keywords: Anti-IgLON5 disease, Psychiatric symptoms, Neurodegeneration, Immunotherapy, Case report.
- Open Access
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 827138
Autoimmune Encephalitis With Psychotic Manifestations and Cognitive Impairment Presenting as Schizophrenia: Case Report and Literature Review
Autoimmune encephalitis is characterized by mental and behavioral symptoms, seizures, and cognitive impairment. The presence of schizophrenia needs to be distinguished from that of autoimmune encephalitis. Herein, we describe the case of a woman who exhibited abnormal mental behavior and cognitive impairment. The patient had experienced similar symptoms more than 20 years previously and had been diagnosed with schizophrenia. The patient's psychotic symptoms improved after treatment with antipsychotic drugs; however, cognitive impairment persisted. She was diagnosed with anti-N-methyl-D-aspartate (NMDA)-receptor concurrent with anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor encephalitis. She showed improvement after treatment with steroids and intravenous immunoglobulins (IVIgs). Furthermore, we reviewed the literature and found that, including the present case, 10 patients have been diagnosed with anti-NMDA concurrent with anti-AMPA-receptor encephalitis. Three of these patients were men and seven were women, and their ages ranged from 21 to 71 years. Moreover, seven (70%) patients had a history of tumors. Symptoms of these patients included psychotic symptoms, varying degrees of consciousness disturbance, seizures, dyskinesia, dystonia, autonomic dysfunction, agitation, and verbal reduction. Brain magnetic resonance imaging findings showed scattered fluid-attenuated inversion recovery hyperintensity in subcortical white matter and/or medial temporal lobe in seven (70%) patients. After combination treatment, including tumor removal and administration of steroids, IVIg, plasma exchange, or immunity inhibitors, the symptoms improved in part of the patients. It is necessary to exclude autoimmune encephalitis for patients with psychiatric manifestations and cognitive impairment. Timely combination therapy is important in anti-NMDA-receptor concurrent with anti-AMPA-receptor encephalitis.
- 14 February 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 827138
Open AccessAutoimmune Encephalitis With Psychotic Manifestations and Cognitive Impairment Presenting as Schizophrenia: Case Report and Literature Review
Autoimmune encephalitis is characterized by mental and behavioral symptoms, seizures, and cognitive impairment. The presence of schizophrenia needs to be distinguished from that of autoimmune encephalitis. Herein, we describe the case of a woman who exhibited abnormal mental behavior and cognitive impairment. The patient had experienced similar symptoms more than 20 years previously and had been diagnosed with schizophrenia. The patient's psychotic symptoms improved after treatment with antipsychotic drugs; however, cognitive impairment persisted. She was diagnosed with anti-N-methyl-D-aspartate (NMDA)-receptor concurrent with anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor encephalitis. She showed improvement after treatment with steroids and intravenous immunoglobulins (IVIgs). Furthermore, we reviewed the literature and found that, including the present case, 10 patients have been diagnosed with anti-NMDA concurrent with anti-AMPA-receptor encephalitis. Three of these patients were men and seven were women, and their ages ranged from 21 to 71 years. Moreover, seven (70%) patients had a history of tumors. Symptoms of these patients included psychotic symptoms, varying degrees of consciousness disturbance, seizures, dyskinesia, dystonia, autonomic dysfunction, agitation, and verbal reduction. Brain magnetic resonance imaging findings showed scattered fluid-attenuated inversion recovery hyperintensity in subcortical white matter and/or medial temporal lobe in seven (70%) patients. After combination treatment, including tumor removal and administration of steroids, IVIg, plasma exchange, or immunity inhibitors, the symptoms improved in part of the patients. It is necessary to exclude autoimmune encephalitis for patients with psychiatric manifestations and cognitive impairment. Timely combination therapy is important in anti-NMDA-receptor concurrent with anti-AMPA-receptor encephalitis.